ciprofibrate has been researched along with Hyperlipidemias in 34 studies
Hyperlipidemias: Conditions with excess LIPIDS in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We observed a case of chronic radiodermatitis which developed after cardiac catheterization, in a patient treated with corticosteroids and ciprofibrate for lupus." | 7.70 | [Chronic radiodermatitis after heart catheterization: the contributing role of ciprofibrate (Lipanor)?]. ( Gironet, N; Jan, V; Lorette, G; Machet, L; Machet, MC; Vaillant, L, 1998) |
| "Mixed hyperlipidemia is a common risk factor for cardiovascular disease." | 6.70 | Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. ( Aguilar-Salinas, CA; Fanghänel-Salmón, G; Gómez Pérez, FJ; González-Valdez, H; Gulías-Herrero, A; Meza, E; Monterrubio-Flores, EA; Montes, J; Sánchez, L, 2001) |
| "We observed a case of chronic radiodermatitis which developed after cardiac catheterization, in a patient treated with corticosteroids and ciprofibrate for lupus." | 3.70 | [Chronic radiodermatitis after heart catheterization: the contributing role of ciprofibrate (Lipanor)?]. ( Gironet, N; Jan, V; Lorette, G; Machet, L; Machet, MC; Vaillant, L, 1998) |
| "Mixed hyperlipidemia is a common risk factor for cardiovascular disease." | 2.70 | Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. ( Aguilar-Salinas, CA; Fanghänel-Salmón, G; Gómez Pérez, FJ; González-Valdez, H; Gulías-Herrero, A; Meza, E; Monterrubio-Flores, EA; Montes, J; Sánchez, L, 2001) |
| "Ciprofibrate did not inhibit thromboxane B 2 synthesis in platelets." | 2.70 | Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects. ( Cibulová, L; Dzúrik, R; Gajdos, M; Huttová, D; Krivosíková, Z; Mongiellová, V; Spustová, V, 2001) |
| "5%), three abandoned because of gastrointestinal adverse effects, six other patients also complaint of gastrointestinal side effects." | 2.68 | [Safety of ciprofibrate. Open study in a Portuguese population]. ( Branco, MC; de Moura, JP; Ferraz, A; Ferreira, MR; Jesus, LC; Pereira, M; Serra e Silva, P; Silva, JM, 1995) |
| "Out of 12 patients with primary hyperlipidemia (HL) included in the study ischemic heart disease was diagnosed in 4 and hypertension stage I-II in 6 patients." | 2.68 | [A trial of the use of the hypolipidemic preparation Lipanor (ciprofibrate) in patients with primary hyperlipidemia]. ( Kotova, LA; Kukharchuk, VV; Rozhkova, TA; Semenova, OA; Tvorogova, MG, 1996) |
| "Fibric acid derivatives may interact with other drugs and the interactions can be of clinical relevance." | 2.39 | Drug interactions with fibric acids. ( Dujovne, CA; Lozada, A, 1994) |
| "Ciprofibrate is a compound newly introduced into the United Kingdom which shares many pharmacokinetic properties with other fibrates." | 2.38 | Ciprofibrate--a profile. ( Betteridge, DJ, 1993) |
| "The ciprofibrate was suspended after the 8th week for a 4 weeks period and the triglyceride and the fibrinogen levels increased whereas the HDL cholesterol level decreased significantly." | 1.31 | [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia]. ( Császár, A; Kovács, I; Tarján, J, 2001) |
| "Ciprofibrate treatment (100 mg/day for 1 month) effected marked reductions in both total plasma LDL and apo B-100 levels (approximately 19% and approximately 23%, respectively)." | 1.29 | Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. ( Bruckert, E; Chapman, MJ; Dejager, S, 1993) |
| " In hyperlipidemic rats ciprofibrate suppresses the increase in blood lipids 33% at a daily dosage of 0." | 1.26 | The results of animal studies with ciprofibrate, a new orally effective hypolipidemic drug. ( Arnold, A; Beyler, AL; McAuliff, JP; Phillips, DK; Powers, LG, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.88) | 18.7374 |
| 1990's | 20 (58.82) | 18.2507 |
| 2000's | 12 (35.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ganotakis, E | 2 |
| Tsimihodimos, V | 2 |
| Bairaktari, E | 2 |
| Rizos, E | 2 |
| Athyros, V | 1 |
| Seferiades, C | 1 |
| Elisaf, M | 3 |
| Mikhailidis, DP | 3 |
| Devroey, D | 1 |
| Velkeniers, B | 1 |
| Duquet, W | 1 |
| Betz, W | 1 |
| Fontaine, C | 1 |
| Guiard-Schmid, JB | 1 |
| Slama, L | 1 |
| Essid, A | 1 |
| Lukiana, T | 1 |
| Rondeau, E | 1 |
| Pialoux, G | 1 |
| Espinosa, RA | 1 |
| Rodríguez-Roa, E | 1 |
| Nagy, E | 1 |
| Mijares, ME | 1 |
| Rodríguez-Larralde, A | 1 |
| Gil, A | 1 |
| Lundberg, U | 1 |
| Carvajal, Z | 1 |
| Castillo, L | 1 |
| Arocha-Piñango, CL | 1 |
| Silva, JM | 2 |
| Branco, MC | 2 |
| Pereira, M | 2 |
| Figueiredo, H | 1 |
| Jesus, LC | 2 |
| de Moura, JP | 2 |
| Ferreira, MR | 2 |
| Serra e Silva, P | 2 |
| Ferraz, A | 1 |
| Giraud, O | 1 |
| Chanu, B | 1 |
| Farge, D | 1 |
| Parrot, F | 1 |
| Brestescher, C | 1 |
| Rouffy, J | 1 |
| Lozada, A | 1 |
| Dujovne, CA | 1 |
| Chandler, HA | 1 |
| Batchelor, AJ | 1 |
| Capps, NE | 1 |
| Bruckert, E | 2 |
| Dejager, S | 1 |
| Chapman, MJ | 2 |
| Betteridge, DJ | 1 |
| McLeod, AJ | 1 |
| Warren, RJ | 1 |
| Armitage, M | 1 |
| Kukharchuk, VV | 1 |
| Rozhkova, TA | 1 |
| Kotova, LA | 1 |
| Tvorogova, MG | 1 |
| Semenova, OA | 1 |
| Knipscheer, HC | 2 |
| de Valois, JC | 1 |
| van den Ende, B | 1 |
| Wouter ten Cate, J | 1 |
| Kastelein, JJ | 2 |
| Cignarella, A | 1 |
| Nastasi, M | 1 |
| Cavalli, E | 1 |
| Puglisi, L | 1 |
| de Maat, MP | 1 |
| Kluft, C | 1 |
| Ramachandran, S | 1 |
| Giles, PD | 1 |
| Hartland, A | 1 |
| Anber, V | 1 |
| Millar, JS | 1 |
| McConnell, M | 1 |
| Shepherd, J | 1 |
| Packard, CJ | 1 |
| Gironet, N | 1 |
| Jan, V | 1 |
| Machet, MC | 1 |
| Machet, L | 1 |
| Lorette, G | 1 |
| Vaillant, L | 1 |
| Ganotakis, ES | 2 |
| Spyropoulos, KA | 1 |
| Jagroop, IA | 2 |
| Byrne, DJ | 1 |
| Winder, AF | 2 |
| Papadakis, JA | 1 |
| Beghin, L | 1 |
| Capps, N | 1 |
| Duhal, N | 1 |
| Davies, J | 1 |
| Staels, B | 1 |
| Luc, G | 1 |
| Dobiásová, M | 1 |
| Frohlich, J | 1 |
| Liberopoulos, E | 1 |
| Miltiadous, G | 1 |
| Harats, D | 1 |
| Yodfat, O | 1 |
| Doolman, R | 1 |
| Gavendo, S | 1 |
| Marko, D | 1 |
| Shaish, A | 1 |
| Sela, BA | 1 |
| Kovács, I | 1 |
| Tarján, J | 1 |
| Császár, A | 1 |
| Aguilar-Salinas, CA | 1 |
| Fanghänel-Salmón, G | 1 |
| Meza, E | 1 |
| Montes, J | 1 |
| Gulías-Herrero, A | 1 |
| Sánchez, L | 1 |
| Monterrubio-Flores, EA | 1 |
| González-Valdez, H | 1 |
| Gómez Pérez, FJ | 1 |
| Lipscombe, J | 1 |
| Bargman, JM | 1 |
| Gajdos, M | 1 |
| Mongiellová, V | 1 |
| Huttová, D | 1 |
| Cibulová, L | 1 |
| Krivosíková, Z | 1 |
| Spustová, V | 1 |
| Dzúrik, R | 1 |
| Arnold, A | 1 |
| McAuliff, JP | 1 |
| Powers, LG | 1 |
| Phillips, DK | 1 |
| Beyler, AL | 1 |
| Petit, D | 1 |
| Bonnefis, MT | 1 |
| Rey, C | 1 |
| Infante, R | 1 |
3 reviews available for ciprofibrate and Hyperlipidemias
| Article | Year |
|---|---|
Drug interactions with fibric acids.
Topics: Anticoagulants; Bezafibrate; Clofibrate; Clofibric Acid; Contraceptives, Oral; Coronary Disease; Dru | 1994 |
Ciprofibrate--a profile.
Topics: Clofibric Acid; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemic Agents | 1993 |
The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy.
Topics: Cardiovascular Diseases; Clofibric Acid; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemic Agents | 1996 |
10 trials available for ciprofibrate and Hyperlipidemias
| Article | Year |
|---|---|
Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
Topics: Analysis of Variance; Cholesterol; Clofibric Acid; Female; Fibric Acids; Fibrinogen; Humans; Hyperli | 2002 |
[Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].
Topics: Adolescent; Adult; Aged; Cholesterol; Clofibric Acid; Coronary Artery Disease; Female; Fibric Acids; | 2006 |
[Effectiveness of ciprofibrate. Open study in a Portuguese population].
Topics: Adolescent; Adult; Aged; Clofibric Acid; Female; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemi | 1995 |
[Safety of ciprofibrate. Open study in a Portuguese population].
Topics: Adolescent; Adult; Aged; Clofibric Acid; Female; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemi | 1995 |
[A trial of the use of the hypolipidemic preparation Lipanor (ciprofibrate) in patients with primary hyperlipidemia].
Topics: Adolescent; Adult; Clofibric Acid; Female; Fibric Acids; Hemodynamics; Humans; Hyperlipidemias; Hypo | 1996 |
Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
Topics: Adult; Aged; Clofibric Acid; Double-Blind Method; Female; Fibric Acids; Fibrinogen; Follow-Up Studie | 1996 |
Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia.
Topics: Adult; Clofibric Acid; Female; Fibric Acids; Fibrinogen; Gemfibrozil; Humans; Hyperlipidemias; Hypol | 1997 |
Homocysteine elevation with fibrates: is it a class effect?
Topics: Adult; Bezafibrate; Clofibric Acid; Dietary Fats; Female; Fibric Acids; Homocysteine; Humans; Hyperl | 2001 |
Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Topics: Adolescent; Adult; Aged; Apolipoproteins B; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, | 2001 |
Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
Topics: Aged; Arteriosclerosis; Aspirin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Fi | 2001 |
21 other studies available for ciprofibrate and Hyperlipidemias
| Article | Year |
|---|---|
Effects of various fibrates on serum alkaline phosphatase activity.
Topics: Alkaline Phosphatase; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; H | 2002 |
Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholestero | 2003 |
Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate.
Topics: Anti-HIV Agents; Clofibric Acid; Dideoxynucleosides; Drug Hypersensitivity; Drug Interactions; Drug | 2005 |
[Acute rhabdomyolysis associated with digestive disorders during a voluntary overdose of ciprofibrate].
Topics: Abdominal Pain; Acute Disease; Adult; Clofibric Acid; Diarrhea; Drug Overdose; Fibric Acids; Humans; | 1995 |
Ciprofibrate and lipid profile.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Fibric Acids; Humans; Hyperlipidemi | 1994 |
Lipid profiles on fibric-acid derivatives.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Female; Fibric Acids; Humans; Hyperlipidemias; Hypoli | 1994 |
Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
Topics: Adult; Apolipoprotein B-100; Apolipoproteins B; Clofibric Acid; Fibric Acids; Humans; Hypercholester | 1993 |
Abnormal lipid profiles on fibrate derivatives.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemic | 1996 |
Novel lipid-lowering properties of Vaccinium myrtillus L. leaves, a traditional antidiabetic treatment, in several models of rat dyslipidaemia: a comparison with ciprofibrate.
Topics: Animals; Anthocyanins; Blood Glucose; Clofibric Acid; Diabetes Mellitus, Experimental; Fatty Acids, | 1996 |
Acute renal failure due to rhabdomyolysis in presence of concurrent ciprofibrate and ibuprofen treatment.
Topics: Acute Kidney Injury; Adult; Anti-Inflammatory Agents, Non-Steroidal; Clofibric Acid; Drug Interactio | 1997 |
Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans.
Topics: Adult; Aged; Aorta; Apolipoproteins B; Arginine; Chondroitin Sulfates; Clofibric Acid; Coronary Arte | 1997 |
[Chronic radiodermatitis after heart catheterization: the contributing role of ciprofibrate (Lipanor)?].
Topics: Cardiac Catheterization; Chronic Disease; Clofibric Acid; Female; Fibric Acids; Glucocorticoids; Hum | 1998 |
Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice.
Topics: Body Weight; Cardiovascular Diseases; Clofibric Acid; Female; Fibric Acids; Fibrinogen; Humans; Hype | 1998 |
Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Clof | 1999 |
Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate.
Topics: Apolipoprotein A-I; Apolipoprotein A-II; Clofibric Acid; Fibric Acids; Humans; Hyperlipidemias; Lipo | 1999 |
[The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].
Topics: Adult; Aged; Arteriosclerosis; Child; Cholesterol; Cholesterol, HDL; Clofibric Acid; Esterification; | 2000 |
Impressive lipid changes following hypolipidaemic drug administration can unveil subclinical hyperthyroidism.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Fibric Acids; Humans; Hyperlipidemias; Hyperthyr | 2001 |
[Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia].
Topics: Adult; Blood Flow Velocity; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Endothelium, Vascula | 2001 |
Fibrate-induced increase in blood urea and creatinine.
Topics: Bezafibrate; Blood Urea Nitrogen; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Humans; Hyp | 2001 |
The results of animal studies with ciprofibrate, a new orally effective hypolipidemic drug.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Cholesterol; Clofibrate; Cyclopropanes; Dru | 1979 |
Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats.
Topics: Animals; Apolipoproteins; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Hyperl | 1988 |